Latest News - Atopic Dermatitis

Tuesday, March 28, 2017 | FDA Approval/Clearance,, Regeneron, Sanofi

FDA Approves New Eczema Drug Dupixent

The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose ec…

Read the full story

Monday, March 20, 2017 |,, Research and Publications

No Antibiotics Needed For Mild Infected Eczema in Kids

Oral or topical antibiotics are not effective for treating milder clinically infected eczema in children, a new study shows. In the study of 113 children with clinical, non-severely infected eczema…

Read the full story

Tuesday, March 07, 2017 |, Research and Publications

New Research Closes In On Personalized AD Therapy

New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermati…

Read the full story

Wednesday, March 01, 2017 |,,,,,, Research and Publications

Skin Diseases Remain Major Cause of Disability

Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimat…

Read the full story

Wednesday, March 01, 2017 |,,,,,, Research and Publications, American Academy of Dermatology

AAD Launches SkinSerious Campaign

The American Academy of Dermatology is launching a new campaign to raise awareness of the breadth of serious skin diseases as well as the critical role dermatologists play in an era of team-based heal…

Read the full story

Monday, February 13, 2017 |, Research and Publications

Intramuscular Flu Shots May Mitigate Staph Risk In AD Patients

Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu…

Read the full story

Friday, February 10, 2017 |, Research and Publications

Cochrane Review: All Moisturizers Created Equally for Eczema

No one moisturizer is better than another when it comes to relieving the symptoms of eczema, according to a new Cochrane Review. Overall, most moisturizers show beneficial effects for eczema, work …

Read the full story

Monday, February 06, 2017 |, Product Launches and Updates, Atopic Dermatitis , Eczema, PuraCap

PuraCap: Video Available to Educate Families, Children

A new video from PuraCap® Pharmaceutical explores the effects of childhood eczema and how parents and kids can find relief. As many as one out of every three kids suffe…

Read the full story

Monday, January 30, 2017 |

Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitis

Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD).  Pending acceptance, the IND will enabl…

Read the full story

Thursday, January 26, 2017 |,,, Research and Publications, Melanoma

Congratulations: American Skin Association Announces 2017 Research Scholar Awards and Research Grants

And the winners are … The American Skin Association (ASA) research scholar awards and research grants are: ASA Carson Research Scholar Award in Psoriasis Cory L. Simpson, MD, PhD Un…

Read the full story

Tuesday, January 17, 2017 |, Product Launches and Updates, Atopic Derm, Atopic Dermatitis

Encore Dermatology Inc. Launches TridesilonTM (desonide) Cream, 0.05% for AD

Encore Dermatology Inc. is rolling out TridesilonTM (desonide) Cream, 0.05% in a 60g tube for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. …

Read the full story

Friday, January 06, 2017 |, Research and Publications

Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritus

Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic…

Read the full story

Wednesday, January 04, 2017 |,,,, Research and Publications

Study Examines Diversity in Dermatologic Clinical Trials

Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, es…

Read the full story

Wednesday, December 21, 2016 | Acquisitions and Mergers,, Product Launches and Updates

Dermavant Licenses Portola Pharma’s Cerdulatinib For Skin Applications

Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor tha…

Read the full story

Wednesday, December 14, 2016 | FDA Approval/Clearance,, Anacor, Pfizer

FDA Approved Eucrisa (Crisaborole) for AD

The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older.  Eucrisa, applied topically twice daily, …

Read the full story
Load More